The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 27, 2018
Filed:
Mar. 31, 2015
Applicant:
Immunovaccine Technologies Inc., Halifax, CA;
Inventors:
Pirouz M. Daftarian, Halifax, CA;
Marc Mansour, Halifax, CA;
Bill Pohajdak, Dartmouth, CA;
Robert G. Brown, Dartmouth, CA;
Wijbe M. Kast, Flintridge, CA (US);
Assignee:
IMMUNOVACCINE TECHNOLOGIES INC., Halifax, CA;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); A61K 9/127 (2006.01); A61K 9/00 (2006.01); A61K 31/4745 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/385 (2006.01); C07K 14/005 (2006.01); C07K 14/47 (2006.01); C12N 9/90 (2006.01); A61K 47/64 (2017.01);
U.S. Cl.
CPC ...
A61K 9/127 (2013.01); A61K 9/0024 (2013.01); A61K 31/4745 (2013.01); A61K 39/00 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/385 (2013.01); A61K 47/646 (2017.08); C07K 14/005 (2013.01); C07K 14/4748 (2013.01); C12N 9/90 (2013.01); A01K 2267/0331 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55544 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/585 (2013.01); A61K 2039/6031 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/622 (2013.01); A61K 2039/627 (2013.01); A61K 2039/70 (2013.01); C07K 2319/00 (2013.01); C12N 2710/20022 (2013.01); C12N 2710/20034 (2013.01); C12Y 503/03012 (2013.01);
Abstract
The invention compositions comprising a continuous hydrophobic phase and liposomes as a vehicle for delivery of an antigen capable of inducing a cytotoxic T lymphocyte (CTL) response and methods for their use in the treatment of cancer.